Zacks Investment Research on MSN
OTLK stock crashes 67% in a week: Here's what you need to know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third ...
Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...
Shares in biopharmaceutical group Outlook Therapeutics ($OTLK) collapsed in pre-market trading after the U.S. Food and Drug ...
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence ...
Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...
The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...
The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...
U.S. futures are trading higher with Nasdaq 100 Futures futures up as much as 1.1% in pre-market Friday. ASML (NASDAQ:ASML) are up 4.9% after Aletheia Capital double-upgraded the European-listed ...
CRANBURY, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback